Despite a trend toward shorter OS in ERBB2‐amplified ILBC (119.6 ± 15.6 months) versus ERBB2‐unamplified ILBC (149.9 ± 6.6 months), Kaplan–Meier survival analysis did not show a statistically significant difference between HER2‐positive and HER2‐negative ILBC, also when only higher tumor stage or positive nodal stage were studied. This evidence concerns the gene ERBB2 and neoplasm.